Description: Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Home Page: www.genenta.com
GNTA Technical Analysis
Via Olgettina No. 58
Milan,
MI
20132
Italy
Phone:
39 02 26 43 46 81
Officers
| Name | Title |
|---|---|
| Mr. Pierluigi Paracchi | Vice Chairman, CEO & GM |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder & Chairman of the Exec. Scientific Board |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder & Member of the Exec. Scientific Board |
| Mr. Richard B. Slansky | Chief Financial Officer |
| Dr. Stefania Mazzoleni Ph.D. | Scientific Director & Communication Officer |
| Dr. Carlo Russo M.D. | Chief Medical Officer & Head of Devel. |
| Mr. Tim Obara | Head of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7031 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |